Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 328Methotrexate 182Cytarabine 164fludarabine phosphate 151Vincristine 128Dexamethasone 126fludarabine 123Peripheral Blood Stem Cell Transplantation 116Whole-Body Irradiation 108Etoposide 106Mycophenolic Acid 105Tacrolimus 95Busulfan 95Filgrastim 93Melphalan 81Cyclosporine 80Rituximab 79Doxorubicin 79Mercaptopurine 69Radiotherapy 62Antilymphocyte Serum 62Granulocyte Colony-Stimulating Factor 57Prednisone 56blinatumomab 55pegaspargase 54Asparaginase 54Thiotepa 52Daunorubicin 52Calcium Dobesilate 47Clofarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Precursor Cell Lymphoblastic Leukemia-Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
22 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03512405 2025-05-30

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1/2 Active not recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡